NEW YORK and LONDON, July 1, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a …
[Read more...] about Akari Therapeutics Announces Appointment of Chief Financial Officer
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC
NEW YORK and LONDON, July 1, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a …
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2020
Notice of Annual Shareholders Meeting 2020 Articles of Association Proxy Form Consolidated Annual Report and Financial Statements 2019 Dear …
[Read more...] about NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2020
Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients
Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid …
Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
Significant Clinical Progress Across Target Indications during 2019 and 2020 Year-to-Date Interim Phase II bullous pemphigoid (BP) data demonstrated a rapid …
